Advertisement
U.S. markets close in 4 hours 40 minutes
Advertisement

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
20.64-0.13 (-0.63%)
As of 11:20AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
Previous Close20.77
Open20.75
Bid20.45 x 1100
Ask20.56 x 800
Day's Range20.36 - 21.35
52 Week Range9.60 - 39.85
Volume67,415
Avg. Volume688,730
Market Cap1.145B
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-2.86
Earnings DateFeb 21, 2024 - Feb 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KYMR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kymera Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/07/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    27 days agoArgus Research
View more
  • GlobeNewswire

    Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

    KT-474 showed evidence of robust target degradation and pathway inhibition with a favorable safety profile in healthy volunteers and patients Trial showed encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), with a systemic anti-inflammatory effect observed in patients with moderate-to-severe disease Study is first published clinical trial using a heterobifunctional degrader Kymera’s partner Sanofi conducting Phase 2 clinical trials of KT

  • GuruFocus.com

    BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc

    On November 3, 2023, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio), a prominent investment firm, increased its holdings in Kymera Therapeutics Inc (NASDAQ:KYMR), a leading biotechnology company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of the guru and the traded company, and the potential implications for value investors. The firm added 414,105 shares of Kymera Therapeutics Inc to its portfolio at a traded price of $14.27 per share.

  • Insider Monkey

    Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript

    Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter 2023 Results Call. [Operator Instructions]. Please note that this event is being recorded. I’d like to turn the conference over to Ms. Justine Koenigsberg, Vice President of Investor Relations. Please go ahead. […]